$Gorilla Technology (GRRR.US)$ Acquisition cost 30😅 switching from ServiceNow, Namu Amida Butsu.

$Gorilla Technology (GRRR.US)$
Good evening meow
Currently, if it breaks through the swing high of 31.78, targets are 31.93/32.86/33.43(33.66)/35.40.
At least 28.69 must be maintained; if it cannot be maintained, the possibility of a breakdown to 27.50(27.41)/26/25/23 increases.
As long as it holds above 27.52, the possibility of continuous increases remains high.
At the very least, holding above 21.83 keeps the possibility of an increase high.
Breaking above 31.78 and ideally holding and breaking 32.86 would increase expectations for next week.
See you later.Goodbye.

【Must-Check! Top 10 Popular Stocks】Welcome to!
Introducing the top 10 stocks that were hot topics within the app last week, all at once.By providing this information, we hope you can gain new perspectives or find opportunities to enhance your investment skills.
In the second week of February (2nd - 8th),the trends of President Trump's tariff policywere the focus of attention worldwide. Changes in President Trump's stance regarding tariffs and actual movescontinued to cause fluctuations in the Market Overview.What kind of stocks attracted attention during this period?
Now, let's begin,Top 10 trending stocksLet's check it out!
1. $NVIDIA (NVDA.US)$ (Attention level ⭐⭐⭐⭐⭐)
In the second week of February, NVIDIA's stock price is,"DeepSeek Shock"of the weekA drop of about 15%.fromA rebound of about 8%.Concerns about the Chinese AI development venture "DeepSeek" have temporarily eased. The company is complying with the USA government's policy regarding export restrictions on high-performance Semiconductors to China.It is providing lower-performance Semiconductors for the Chinese market.However,the uncertainty of President Trump's policy towards Chinastill remains....

$Rigetti Computing (RGTI.US)$
Good evening meow~n
Gold has pulled back on Friday, hasn't it?There is a bounce at the confluence point where the Extension 100.0% matches in 2 points
Currently, there is a possibility of retesting 11.87, but if the pullback is completed, it is better to hold & break above 13.51.At least hold above 13.12 (13.10).
Bullish on the put-call ratio.Breaking 13.10 and entering the 13 zone, perhaps?
If the continuous upward trend is maintained, it's advisable to hold & break above 14.45.
See you later.Goodbye.

Investors expect an increase in Datacenter IPOs, driven by AI infrastructure demand.February 7, 2025 15:15 JST (partial excerpt)
CoreWeave and Northern Data, among other operations companies, plan to launch IPOs in the USA.
Blackstone predicts over 1 trillion dollars in US Datacenter investments within 5 years.
Investors are focusing on the United States' datacenters supporting the Artificial Intelligence (AI) boom, and a handful of upcoming initial public offerings (IPOs) scheduled for 2025 are likely to meet their investment appetite.
One of the most watched startups in the AI field, the cloud computing provider CoreWeave is planning an IPO early this year, with a valuation expected to exceed 23 billion dollars (approximately 3.5 trillion yen). By the end of 2024, the company operates 28 datacenters worldwide and receives support from major technology companies such as NVIDIA and Cisco.
Northern Data, listed on the Frankfurt market in Germany, is considering listing its AI and datacenter business integration division in the US market.
According to Bloomberg, the operation of datacenters in China...

$Advanced Micro Devices (AMD.US)$
Despite waiting and waiting, no signs of recovery were seen, and the financial results did not seem very good, so I cut my losses at around $107, which was close to the bottom. Instead,
$Gorilla Technology (GRRR.US)$ Increased the Buy.

$Tempus AI (TEM.US)$ $Palantir (PLTR.US)$ $Spotify Technology (SPOT.US)$ $Reddit (RDDT.US)$ $Hims & Hers Health (HIMS.US)$ $Robinhood (HOOD.US)$
I wanted to try swing trading, so I sold all the stocks that were in unrealized losses since last month and only held positions in uptrend stocks for asset management. The performance has improved significantly 🤑 This method seems suitable for those who have a liking for gambling 😆.
Because I make a lot of decisions, it's extremely tiring until I get used to it, but I feel it is the beauty of individual stock management. (I made 12 trades last night. It feels good to press the order button once you get used to it 😁)
⭐️Things to be aware of
If you are afraid of gambling in financial statements, do not take risks. Dispose of stocks involved in range trading and unrealized losses immediately (such as Spotify and Sofi, which have already been sold across financial statements). Unrealized losses of over 20% are out of the question. By cutting stocks with large unrealized losses, your portfolio will only consist of clean gains, and you'll feel good.
⭐️Things I'm doing
Engaging in politics in spare time...

Novo Nordisk A S Spons Adr is expected to see significant revenue growth this year – the performance of "Ozempic" continues to be strong.February 5, 2025, 19:20 JST.
This year's revenue growth rate is expected to be between 16% and 24%, with an operating profit increase estimated at up to 27%.
The financial results for October to December last year also exceeded expectations, and the stock price surged by as much as 6.3% at one point.
The Danish Drug Manufacturers, Novo Nordisk A S Spons Adr, expect a significant increase in revenue this year, driven by the expansion of supply for its main diabetes treatments, "Ozempic" and weight loss drug "Wegovy."
According to the company's announcement on the 5th, excluding the impact of exchange rate fluctuations, a revenue increase of 16-24% is anticipated this year. Last year saw a 26% revenue increase. Following this forecast and the better-than-expected financial results for the fourth quarter of last year (October-December), the stock price in the Copenhagen market surged by as much as 6.3%.
In October-December of last year, revenue reached 85.7 billion Danish kroner (approximately 1 trillion 830 billion yen), exceeding Analyst expectations, with Ozempic and Wegovy also growing as predicted. This year's operating profit, excluding the impact of exchange rate fluctuations, is expected to increase by up to 27%, outpacing revenue growth.
In recent months, Novo has continuously faced competition from Eli Lilly and Co.